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Abstract Phenylketonuria (PKU) is caused by mutations
in the gene encoding phenylalanine hydroxylase (PAH)
enzyme. Here, we report the updated spectrum of PAH
mutations in 61 Serbian PKU patients. By using both
DGGE/DNA sequencing and PCR-RFLP, we identified 26
disease-causing mutations (detection rate 99%). The most
frequent ones were p.L48S (31%), p.R408W (16.4%),
p.P281L (6%), p.E390G (5.2%), and p.I306V (5.2%).
Homozygosity value indicated high heterogeneity of
Serbian population.
To overcome possible pitfalls of patients’ phenotypic
classification, we used two parameters: pretreatment/maxi-
mal phenylalanine blood concentration and Phe tolerance.
The two phenotypes did not match only for patients with
p.L48S. Therefore, we used Mann-Whitney statistical test
to compare pretreatment/maximal blood Phe concentration
and Phe tolerance detected in patients with p.[L48S];[null]
and p.[missense];[null] genotypes. For patients with
p.L48S, our results implied that Phe tolerance is a better
parameter for phenotypic classification. Also, Fisher’s exact
test was used to compare p.L48S effect on phenotype of
homozygous and functionally hemizygous patients. Our
findings showed that effect of p.L48S was altered in
functional hemizygotes. Moreover, phenotypic inconsis-
tency found in homozygotes suggested that interallelic
complementation and/or additional factors play a role in
genotype-phenotype correlation.
Since BH4-supplementation therapy is not available in
Serbia, we made the first estimation of its potential benefit
based on patients’ genotypes. In the analyzed cohort, the
total frequency of BH4-responsive mutations was 52.6%.
Furthermore, we found a significant number of genotypes
(26.2% BH4-responsive and 51% probably BH4-responsive)
that may respond to BH4 therapy. This led us to a conclusion
that BH4-supplementation therapy could bring benefit to
Serbian PKU patients.
Introduction
Phenylketonuria (PKU, MIM#261600) is the most severe
form of hyperphenylalaninemia (HPA). It is a metabolic
pathology that represents the paradigm of hereditary disease
that can be treated. With the average incidence of 1 per
10,000 newborns, PKU is considered to be the most
common inborn error of amino acid metabolism in
Caucasians and one of the most studied rare diseases
(Scriver et al. 2008).
Hyperphenylalaninemias are a result of deficient hepatic
enzyme, phenylalanine hydroxylase (PAH, EC 1.14.16.1).
PAH is responsible for the conversion of phenylalanine (Phe)
into tyrosine, in the presence of the molecular oxygen and
cofactor tetrahydrobiopterin (BH4). If this metabolic path-
way is impaired, tyrosine becomes an essential amino acid
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while the concentration of phenylalanine rises above normal.
Deficiency of the PAH enzyme is caused by mutations in the
phenylalanine hydroxylase gene (PAH, GenBank accession
no. AF404777). PAH gene is mapped to human chromosome
12q24.1, it spans approximately 90 kb and contains 13 exons
and 12 large introns (Scriver 2007).
PKU is a monogenic disease which is transmitted in an
autosomal recessive pattern and the two mutations found in
the patient’s genotype stand as the main determinant of
PKU phenotype (Kayaalp et al. 1997; Guldberg et al.
1998). The knowledge about mutations in the PAH gene
and their effect on the phenotype is the best example of
nutrigenetics – a new scientific discipline with a goal to
develop an optimal diet based on genotype analysis (Guttler
and Guldberg 2000; Fenech et al. 2011). Nevertheless, the
PKU phenotype is not simple and there are numerous
factors (genetic and nongenetic) that contribute to its
complexity (Scriver and Waters 1999; Dipple and McCabe
2000).
More than 600 different mutations have been identified
in PAH gene and recorded in the literature and the PAH
locus knowledgebase (Scriver et al. 2003, http://www.
pahdb.mcgill.ca). Depending on mutation type (missense,
nonsense, splice site, small or large insertions and dele-
tions) and position (regulatory, catalytic, or tetramerization
domain), the effect of a mutation on the structure and
activity of the PAH varies greatly. As a consequence, the
activity of mutant protein ranges from 0% to almost 100%
compared to normal PAH enzyme (Waters et al. 1998).
Correspondingly, hyperphenylalaninemic phenotypes range
from mild hyperphenylalaninemia (MHP) that does not
require treatment to a classic PKU characterized by severe
mental retardation and epilepsy in the absence of treatment.
Furthermore, the effect of some mutations on PAH activity
and PKU phenotype is steady and consistent through
numerous in vitro and in vivo studies performed in different
populations, while for others its effect is inconsistent and
unpredictable. While mutations with a consistent effect
enable accurate prediction of PKU phenotype based on
genotype, PKU phenotype becomes more complex in case
of mutations with an inconsistent effect.
For more than two decades, efforts had been made to
fully understand the effect of mutations on PKU phenotype.
However, there is ongoing need to further analyze
mutations in genotype-phenotype correlation studies, par-
ticularly in the group of patients of identical genotype and
genetic background.
Recently, a new therapeutic approach is becoming a
valid option for the dietary treatment of PKU patients. It
relies on the observation that pharmacological doses of the
tetrahydrobiopterin (BH4), a natural cofactor of PAH
enzyme, can lower blood phenylalanine concentration
(Kure et al. 1999). Molecular mechanism of BH4 action
is multifactorial, but mainly based on its chaperon-like
activity which results in the stabilization of altered
conformations of PAH enzyme. By binding to an unstable
enzyme, BH4 protects it from degradation, prolongs its
half-life and enables it to perform conversion of phenylala-
nine to tyrosine. (Erlandsen et al. 2004; Pey et al. 2004;
Pérez et al. 2005). The BH4-supplementation therapy
(Kuvan) can be used to loosen or even replace burdensome
dietary treatment of PKU patients (Levy et al. 2007a; Trefz
et al. 2009b). However, not all PKU patients are BH4
responsive, meaning that at the molecular level, not all
mutated proteins benefit from the increased concentration
of BH4. In order to understand which mutations are good
candidates, many studies analyzed the enzyme activity of
mutated enzymes in vitro in the presence of BH4 precursors
(Kim et al. 2006; Aguado et al. 2007). Also, it was shown
that PAH function and response to BH4 administration
result from interplay between genotype, metabolic state,
and cofactor concentration (Staudigl et al. 2011). Several
studies analyzed the correlation of genotype and patient’s
responsiveness to BH4 and made an attempt to predict the
BH4-responsiveness on the basis of genotype (Zurfl€uh et al.
2008; Karacic et al. 2009; Rivera et al. 2011; Sterl et al.
2012). In the Kuvan era, genotypization of patients became
important, not only because of the definitive diagnosis and
prediction of the optimal diet, but also to point out those
patients that could benefit from new therapeutic approach.
BH4 loading test is a definitive diagnostic test for
cofactor sensibility. However, estimation based on genotyp-
ing answers an important question in countries where BH4
is not an approved drug: Is the frequency of BH4
responsive mutations in a population high enough to
consider giving opportunity to patients for a new therapeutic
method?
The first study on Serbian PKU population was
performed 6 years ago (Stojiljkovic et al. 2006). Here, we
presented molecular and phenotypic characteristics of
enlarged cohort of Serbian PKU patients with focus on
phenotypic effect of the most frequent mutation, p.L48S
(c.143T>C). We discussed possible pitfalls of phenotypic
classification of PKU patients and genotype clustering
that could influence genotype-phenotype correlation
studies. Also, we assessed the potential benefit from
BH4-supplementation therapy in Serbia.
Subjects and Methods
Patients and Phenotypic Classification
In this study, 61 patients with hyperphenylalaninemia from
Serbia (comprising three pairs of siblings) were included.
Also, 10 parent samples were analyzed in order to facilitate
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and clarify mutation detection of a patient or to explain
phenotypic status of a mother. Neonatal screening was
established in Central Serbia in 1982, and in 2003 it was
expanded to Vojvodina (Serbian Northern province).
According to regional agreement, it was recommended to
start with dietary regiment if the pretreatment phenylalanine
level exceeded 360 mmol/l. Although most patients
included in this study were detected by the newborn
screening program, 16 children were diagnosed later in life
during evaluation of psychomotor retardation or by routine
measurement of blood Phe level at the Mother and Child
Healthcare Institute “Dr Vukan Cupic” in Belgrade.
Clinical data collected include: pretreatment and maxi-
mal phenylalanine blood concentration, phenylalanine
tolerance, IQ, age at the diagnosis, the application of low
Phe diet, and other relevant data. The phenylalnine
tolerance is the highest amount of Phe from food that a
patient can tolerate to keep blood Phe concentrations in the
safe range (120–360 mmol/l) (Guldberg et al. 1998). It is
possible to reliably assess Phe tolerance already at the age
of 2 years (van Spronsen et al. 2009).
In this study, patients were classified into three catego-
ries according to pretreatment/maximal phenylalanine
blood level and according to phenylalanine tolerance:
classical PKU (pretreatment Phe >1200 mmol/l; Phe
tolerance <20 mg/kg/day – equivalent 250–350 mg/day),
mild PKU (pretreatment Phe 600–1200 mmol/l; Phe
tolerance 20–25 mg/kg/day – equivalent 350–600 mg/
day), and MHP (pretreatment Phe <600 mmol/l; Phe
tolerance >25 mg/kg/day – equivalent >600 mg/day)
(Trefz et al. 1985; Guldberg et al. 1998). The pretreatment
level is a quantitative blood/serum Phe measurement under
standardized condition. Phe tolerance was determined in
cooperation with the patient/parents or during hospitaliza-
tion. Maximal Phe level is the highest pretreatment blood
Phe concentration (mmol/L) or the highest Phe in the
loading Phe test (180 mg/kg/day) if performed.
This study was approved by the Ethics Committee at the
Mother and Child Healthcare Institute “Dr Vukan Cupic”
and all parents and/or patients gave informed consent. They
were further referred to the Institute of Molecular Genetics
and Genetic Engineering, University of Belgrade, for
molecular genetic analysis.
Molecular Genetic Analysis
Genomic DNA was extracted from peripheral blood by
QIAamp DNA Blood Mini Kit. Mutations were identified
by multiplex “broad range” denaturing-gradient gel electro-
phoresis (DGGE) (Guldberg and Guttler 1994) followed by
DNA sequencing (ABI Prism BigDye Terminator Cycle
Sequencing Ready Reaction Kit, in an ABI PRISM 310
Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). When necessary, PCR-RFLP or PCR-ACRS analy-
ses for several common point mutations (p.L48S
(c.143T>C), p .R408W (c.1222C>T), p .R261Q
(c.782G>A), p.R261X (c.781C>T), IVS10-11G>A
(c.1066-11G>A), and p.R158Q (c.473G>A)) were also
performed (Eiken et al. 1993).
We used referent sequence (GenBank accession no.
AF404777) to identify changes in PAH gene and HGVS
guidelines for nomenclature of genetic variants. Also, we
used the PAH locus knowledgebase (PAHdb, http://www.
pahdb.mcgill.ca) and literature found on PubMed to
determine if a mutation has already been reported.
Results
Genotyping
This study included molecular characterization of 61
Serbian patients with hyperphenylalaninemia. Given that
the cohort included three pairs of siblings, we analyzed the
total number of 116 unrelated mutant alleles. On 113
mutant alleles we identified one disease-causing mutation,
and, interestingly, on two unrelated mutant alleles we
detected two disease-causing mutations. Since 115 out of
116 PAH alleles were characterized, the mutation detection
rate in this study was 99%. High diagnostic efficiency was
achieved by combining PCR-RFLP and DGGE/DNA
sequencing analysis of PAH gene. Additionally, our genetic
analysis established PKU diagnosis for two patients’
mothers that have not been diagnosed before.
In this cohort of Serbian patients, we identified 26
different disease-causing mutations. Seven of them were
not reported in the previous study on Serbian population.
The frequency of the most typical Serbian mutation, p.L48S
(c.143T>C), is 31%. Other significant mutations had the
following frequencies: 16.4% of p.R408W (c.1222C>T),
6% of p.P281L (c.842C>T), 5.2% of p.E390G
(c.1169A>G), and 5.2% of p.I306V (c.916A>G). These
five mutations accounted for almost two thirds of all mutant
alleles in the Serbian population. The remaining mutations
are listed in Table 1. Calculated homozygosity value was
expectedly low (0.14), confirming the mutational heteroge-
neity of PAH locus for Serbian population.
Genotypic homozygosity was observed in 12 unrelated
patients for the following mutations: p.L48S, p.R111X,
p.R243X, p.P281L, and p.R408W. Among them, there were
8 [p.L48S];[p.L48S] genotypes. Interestingly, homozygos-
ity for p.I306V mutation was detected in two additional
cases. However, presence of the third disease-causing
mutation was also confirmed in these patients’ genotypes:
p.[R261Q; I306V]; [I306V] and p.[R408W; I306V];
[I306V].
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PKU mutations were variously combined into 39
different genotypes, among which 33 genotypes were not
present in more than one family. The relative frequency of
unrelated genotypes that included p.L48S mutation was
48% (28/58).
Phenotypic Characterization
All PKU patients were assigned to phenotypic category
according to pretreatment/maximal blood Phe concentration
level. The analyzed cohort included 34 classical PKU
(58.6%), 14 mild PKU (24.2%), and 10 MHP (17.2%)
patients.
In the majority of cases, phenylalanine tolerance was
used as an additional parameter for classification of PKU
patients. We compared phenotype categories based on two
different parameters and found that patients without p.L48S
in the genotype had matching categories according to both
parameters. However, for almost 20% of patients carrying
p.L48S, phenotype category based on pretreatment/
maximal blood Phe concentration was more severe than
the phenotype obtained by Phe tolerance. In order to further
analyze observed discrepancies, we listed detailed pheno-
type characteristics and other relevant data (e.g., start and
compliance to the low Phe diet) for homozygous and
heterozygous p.L48S patients (Table 2).
Furthermore, we used Mann-Whitney test to compare
pretreatment/maximal blood Phe concentration and Phe
tolerance for p.[L48S];[null] and p.[missense];[null] geno-
types. We have found that patients with p.[L48S];[null]
genotype had significantly higher pretreatment Phe concen-
trations (p ¼ 0.001).
Table 1 Spectrum and frequency of mutations causing PKU in Serbia
Mutations
Exon Number of chromosomes Relative frequency (%) Type of mutationTrivial name Systematic name
p.S16fs c.47_48delCT 1 1 0.9 Frameshift
p.Q20X c.58C > T 1 2 1.7 Nonsense
p.L48S c.143T > C 2 36 31.0 Missense
p.R111X c.331C > T 3 3 2.6 Nonsense
p.R158Q c.473G > A 5 4 3.4 Missense
p.V177L c.529G > C 6 3 2.6 Missense
p.V177M c.529G > A 6 1 0.9 Missense
p.L213P c.638T > C 6 1 0.9 Missense
p.P225T c.673C > A 6 3 2.6 Missense
p.S231F c.692C > T 6 1 0.9 Missense
p.R243X c.727C > T 7 2 1.7 Nonsense
p.R252Q c.755G > A 7 1 0.9 Missense
p.R261Q c.782G > A 7 4 3.4 Missense
p.R261X c.781C > T 7 2 1.7 Nonsense
p.P281L c.842C > T 7 7 6.0 Missense
p.R297H c.890G > A 8 1 0.9 Missense
p.I306V c.916A > G 9 6 5.2 Missense
IVS10 þ 3A > G c.1065 þ 3A > G * 1 0.9 Splice site
IVS10-11G > A c.1066-11G > A * 2 1.7 Splice site
p.E390G c.1169A > G 11 6 5.2 Missense
p.A403V c.1208C > T 12 2 1.7 Missense
p.R408W c.1222C > T 12 19 16.4 Missense
p.R413P c.1238G > C 12 1 0.9 Missense
p.Y414C c.1241A > G 12 2 1.7 Missense
p.P416Q c.1247C > A 12 1 0.9 Missense
IVS12 + 1G > A c.1315 + 1G > A * 3 2.6 Splice site
Unspecified 1 0.9
Total 116



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Genotype-phenotype correlation study was performed for
patients homozygous for the mutation or functionally
hemizygous patients (the mutant allele is combined with
null mutation and therefore acts on its own). Nonsense,
frameshift, and splice site mutations, as well as missense
mutations which resulted in zero enzyme activity in vitro,
were considered as null mutations (Kayaalp et al. 1997;
Guldberg et al. 1998). Patients with three mutations in the
genotype were not taken into account.
The most frequent mutation, p.L48S, is known to have
an inconsistent phenotypic outcome (Guldberg et al. 1998).
To avoid the effect attributable to interallelic interaction, we
separately analyzed genotype-phenotype correlation for
8 p.[L48S];[L48S] and 11 p.[L48S];[null] patients. Also,
we analyzed genotype-phenotype correlation when pheno-
types were classified according to pretreatment blood Phe
concentration and according to Phe tolerance. We used
Fisher’s exact test to compare the effect of p.L48S on
phenotype in homozygous versus functionally hemizygous
patients. We found that distribution of phenotypes signifi-
cantly varied between two genotype groups (p ¼ 0.018 and
p ¼ 0.039, respectively). Interestingly, when functionally
hemizygous p.L48S genotypes were correlated with phe-
notypes determined according to pretreatment blood Phe
concentration, these genotypes were associated with classi-
cal PKU in 100% cases. On the other hand, p.L48S
homozygotes were associated with all three phenotype
categories determined according to Phe tolerance.
We also analyzed the effect of several other missense
mutations found in functional hemizygotes. We found that
p.P225T, p.R261Q, and p.R413P mutations were associated
with classical PKU, p.V177L and p.R297H with mild PKU,
while p.I306V and p.A403V were associated with MHP.
The inconsistency was noticed for p.E390G mutation which
was found in patients with one classical PKU, three mild
PKU, and one MHP phenotype.
BH4 Responsiveness
The p.L48S mutation as well as seven others (p.R158Q,
p.R261Q, p.I306V, p.E390G, p.A403V, p.R413P, and
p.Y414C) were characterized as BH4-responsive ones in
previous European studies (Zurfl€uh et al. 2008; Trefz et al.
2009a; Karacic et al. 2009). Accordingly, the sum of
relative frequencies of BH4-responsive mutations for
Serbian population is 52.6%.
However, some mutations have the status of consistently
BH4-responsive while others are considered as inconsis-
tently responsive. According to the classification given in
Sterl et al. (2012), we classified all 39 Serbian PAH
genotypes into BH4 responsive (26.2%), probably BH4
responsive (51%), and non-BH4 responsive (22.8%)
(Table 3). Furthermore, we made distinction between
genotypes with one and two BH4-responsive alleles.
Discussion
This is an update study on molecular genetics of Serbian
hyperphenylalaninemic patients and the first study that
estimates potential of BH4-supplementation therapy based
on patients’ genotypes. Furthermore, we conducted geno-
type-phenotype correlations to analyze phenotypic effect of
mutations.
Unlike recent studies conducted in European PKU
patients, all mutations identified in this cohort of patients
have already been reported in the literature (Sterl et al. 2012;
Groselj et al. 2012). However, the mutational spectrum was
enlarged with seven mutations that were not reported in the
previous study on Serbian population. Furthermore, five
mutations accounted for almost two thirds of all mutant
alleles and the homozygosity value was low. All these
findings indicated rather high heterogeneity of Serbian
population. As it was stated previously, genetics of PAH
locus is concordant with historically documented migra-
tions across the Western Balkans (Stojiljkovic et al. 2006).
Mutation p.L48S reassured its status as the most frequent
in Serbia. Interestingly, its relative frequency (31%) is the
highest ever reported in any population. This mutation was
initially detected in a Turkish patient with phenylketonuria
(Konecki et al. 1991). Since then it has been identified in
many European populations usually with a frequency of
2–5% (Zschocke 2003). Higher frequencies have been
found in Croatian (10%), Italian (9.7%), and Turkish (7%)
populations which are geographically and historically
interconnected with the Serbian population (Giannattasio
et al. 2001; Karacic et al. 2009; Dobrowolski et al. 2011).
In the preliminary haplotype study of patients with p.L48S,
it was shown that the mutation was imported to Serbia from
populations with different genetic backgrounds (Stojilj-
kovic et al. 2007).
Mutation p.R408W remains the second frequent Serbian
mutation. It is the most prevalent mutation worldwide,
which is associated with two different haplotypes and in
Slavic populations it follows the cline distribution from
Baltic to Mediterranean countries (Zschocke 2003). Since
its frequency is 84% in Estonia, 46% in Slovakia, and 36%
in Croatia, detected frequency in Serbia (16.4%) fits into
the established gradient distribution. Mutations p.P281L
and p.E390G are relatively common in Balkans, but rare in
other European populations. Thus, p.P281L was found on
10% alleles in Greece, 8.4% in Turkey, 8% in Croatia, and
6% in Serbia, while p.E390G accounted for 7% of alleles in
Croatia, 5.2% in Serbia, and 4.1% in Turkey (Zschocke
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2003; Karacic et al. 2009; Dobrowolski et al. 2011).
Although mentioned frequencies are quite similar, we could
observe gradient from southeast to northwest for p.P281L
and the inverse for p.E390G.
Interestingly, we found two unrelated patients with three
PKU mutations. Although it is rarely found that a PKU
patient carries three mutations, our finding highlights the
need to screen the complete PAH gene in order to accurately
define PKU genotype. It is possible to imagine that
incomplete genotyping could also lead to inaccurate
conclusions regarding genotype-phenotype correlation.
Genotype-Phenotype Inconsistencies
Analysis of mutation’s effect, based on genotype-pheno-
type correlation, could encounter a problem of inadequate
phenotype classification. Up to date, two distinct parame-
ters have been widely used for phenotype classification.
The first parameter, pretreatment blood Phe level was quite
helpful in the past and was convenient because it was
known for every diagnosed patient. However, this parameter
corresponded mostly to the screening Phe level. The second
one, phenylalanine tolerance, depicts more realistically the
ability of a patient to metabolize Phe from the food.
Unfortunately, there are no universal guidelines which
parameter should be used for classification of HPA patients.
In order to overcome possible pitfalls of patients’ phenotypic
classification, we used both parameters.
Among the most frequent mutations in this study, we
found two null mutations (p.R408W and p.P281L) and two
missense mutations (p.L48S and p.E390G) known to have
inconsistent phenotypic effect. Therefore, Serbian cohort
was suitable and interesting for investigation of genotype-
phenotype correlation in homozygous and functionally
hemizygous patients. Given that the inconsistency noticed
for p.E390G mutation was found in a small number of
patients, we further focused on p.L48S mutation. It is worth
noting that other missense mutations, analyzed in genotype-
phenotype correlation, showed consistent effects which
were already known in the literature.
Our results from Mann-Whitney statistical test for
patients carrying p.L48S implied that categorization based
on Phe tolerance instead of pretreatment blood Phe
concentration is particularly important for patients carrying
Table 3 Genotype-based estimation of BH4-responsiveness in Serbian PKU patients
BH4 responsive Probably BH4 responsive Non-BH4 responsive
R + IR R + N IR + IR IR + N N + N
26.2% 51% 22.8%
7% 19.2% 21% 30% 22.8%
p.[I306V];[L48S] (2) p.[I306V];[R261X] (1) p.[L48S];[L48S] (8) p.[L48S];[Q20X] (1) p.[R408W];[V177L] (1)
p.[I306V];[R261Q] (1) p.[I306V];[R408W] (1) p.[L48S];[R158Q] (3) p.[L48S];[V177L] (1) p.[R408W];[P225T] (1)
p.[E390G];[R158Q] (1) p.[I306V];[P416Q] (1) p.[L48S];[R261Q] (1) p.[L48S];[V177M] (1) p.[R408W];[R252Q] (1)
p.[E390G];[R261X] (1) p.[L48S];[P225T] (1) p.[R408W];
[IVS10 + 3A > G] (1)
p.[E390G];[P281L] (1) p.[L48S];[S231F] (1) p.[R408W];[R408W] (1)
p.[E390G];[R408W] (3) p.[L48S];[P281L] (2) p.[P281L];[P225T] (1)
p.[A403V];[R408W] (1) p.[L48S];[R408W] (7) p.[P281L];[P281L] (1)
p.[Y414C];[IVS10-
11G > A] (1)
p.[R261Q];[L15fs] (1) p.[P281L];
[IVS12 + 1G > A] (1)
p.[Y414C];[L213P] (1) p.[R261Q];
[IVS12 + 1G > A] (1)
p.[R111X];[R111X] (1)
p.[R413P];[R408W] (1) p.[R111X];[IVS10-




[IVS12 + 1G > A] (1)
PAH mutations are designated as: R – responsive, IR – inconsistently responsive, and N – nonresponsive/unknown to be responsive according to
BH4 responsiveness reported in previous studies (Muntau et al. 2002; Zurfl€uh et al. 2008; Trefz et al. 2009a; Karacic et al. 2009; Sterl et al. 2012)
and according to BIOPKU db. Between parentheses is the number of the same genotypes detected in Serbian PKU patients. Genotype with one
unidentified mutation was excluded from the table
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p.L48S mutation. Furthermore, Fishers’s exact test sug-
gested that the effect of p.L48S mutation is more reliably
determined in the correlation of homozygous genotypes and
phenotypes based on Phe tolerance. In this study, the
majority of p.L48S functionally hemizygous patients had
classical PKU phenotype. However, when p.L48S mutation
was found in the homozygous form, its inconsistent nature
susceptible to different influences became obvious. There-
fore, we could conclude that the real effect of p.L48S was
masked if the mutation was combined with a null mutation.
For some mutations, such as p.I65T, inconsistency could
be explained by interallelic complementation between
different subunits of heterotetrameric PAH (Leandro et al.
2006; Leandro et al. 2011). This mutation is frequent in
Western European populations (Spanish, Portuguese,
French, British, and Norwegian) while it is not frequent in
Slavic populations (Zschocke 2003). It is worth mentioning
that both mutations (p.L48S and p.I65T) in a homozygous
state tend to produce a milder degree of PKU than when
associated with a null allele, demonstrating that each of the
two mutations encode residual PAH activity (39% and
26.5%, respectively). Although p.L48S has not been
studied for interallelic complementation effect, comparison
between homozygous vs. functionally hemizygous Serbian
patients showed that p.L48S residual activity (39%) was
decreased in interaction with null residual activity PAH
subunit. Thus, our finding implies existence of negative
interallelic complementation in functionally hemizygous
p.L48S patients.
Interallelic complementation is only one of the possible
explanations for mutation’s inconsistency. Phenylalanine
concentration in the peripheral circulation is controlled by
various genetic loci and modifying factors at least at two
different levels (Scriver and Waters 1999; Dipple and
McCabe 2000). At the cellular level, a variant PAH enzyme
with disturbed stability is susceptible to enhanced degrada-
tion. However, if there is a flaw in proteolytic degradation
system or a defect in chaperones, both of which could
be genetically determined, it would to some extent have
influence on the blood Phe concentration. At the level of
the whole organism, blood Phe concentration could be
influenced by alterations in Phe absorption in the gut or
variations in the transport of Phe through the hematoence-
phalitic barrier. The identification and characterization of
modifier genes involved in the determination of phenylke-
tonuria phenotype is the field that needs to be explored.
Furthermore, it has been shown that the genetic variant
in the intron of PAH gene has the ability to regulate gene
expression (Stojiljkovic et al. 2010). Numerous variants are
embedded in the large noncoding regions of PAH gene, and
their effect remains unknown. Therefore, variants found in
introns as well as those found upstream and downstream of
the gene coding region should be further investigated.
Since we noticed inconsistency in identical genotypes of
patients with the same population background, it could be
expected that variations in modifier genes would provide an
answer to interindividual rather than interpopulation incon-
sistencies.
BH4 Responsiveness in Serbia
The first study which suggested that BH4-responsiveness
could be deduced from PAH genotype stated that at least
one BH4-responsive mutation would be enough to lead to
the physiological BH4 responsiveness (Zurfl€uh et al. 2008).
In this study on Serbian PKU patients, total frequency of
BH4-responsive mutations was 52.6%.
Later on, it became clear that BH4-responsive genotype
has a greater BH4-responsive predictive value (Trefz et al.
2009a; Karacic et al. 2009). In order to make the most
accurate estimation of the potential of BH4-supplementation
therapy, we classified Serbian PAH genotypes into BH4
responsive, probably BH4 responsive, and non-BH4 respon-
sive (Table 3) (Sterl et al. 2012). Furthermore, we made
distinction between genotypes with one and two BH4-
responsive alleles. Previously, Zurfluh and colleagues postu-
lated that BH4 responsiveness ought to be in the 17–79%
range in European populations with a north to south gradient
(Zurfl€uh et al. 2008). Accordingly, we found that only 22.8%
of patients could not benefit from BH4 therapy and that as
much as 77.2% of PKU population should be subjected to a
standardized BH4 loading test.
Genotype p.[L48S];[L48S] is among the most frequent
genotypes reported in the BIOPKU database (www.biopku.
org). It was reported that when patients carrying this
genotype were subjected to BH4 loading test, they were
found to be responders, slow responders, or partial respond-
ers. Patients with p.[L48S];[R408W] genotype, which could
be regarded as probably responsive according to the
genotype, were frequently reported as nonresponders in
reality. Interestingly, similar to our findings on phenotypic
effect of p.L48S, Karacic et al. observed regularity in p.L48S
BH4 responsiveness. They found that p.L48S tends to be a
nonresponder in functional hemyzigotes, while it usually acts
as a responder in homozygotes (Karacic et al. 2009).
Without a doubt, BH4 loading test is the only way to
determine BH4 responsiveness (Blau et al. 2009; Levy
et al. 2007b). However, the genotype-based estimation is
valuable for countries where BH4 is not yet included in the
drug lists. This study, which represents the first estimation
on BH4 responsiveness for Serbian population, led us to a
conclusion that BH4 supplementation therapy could bring
benefit to Serbian PKU patients.
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Synopsis
Analysis of Serbian PKU patients showed that Phe
tolerance was a better parameter for phenotypic classifica-
tion of patients carrying p.L48S mutation and the genotype
study identified significant number of individuals that may
respond to BH4 supplementation therapy.
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